Recent Quotes (30 days)

You have no recent quotes
chg | %

Dechra Pharmaceuticals plc news

   Watch this stock
Showing stories 1 - 10 of about 80   

Articles published

DPH 1,242.31 +6.31 (0.51%)
price chart
Is Dechra Pharmaceuticals plc a better buy than GlaxoSmithKline plc after ...
Pharmaceutical giants Dechra Pharmaceuticals (LSE: DPH) and GlaxoSmithKline (LSE: GSK) took divergent paths in Monday morning business despite both releasing positive updates.
Dechra Pharmaceuticals PLC, Agrees Acquisition of US-based Putney, Inc for ...
Dechra Pharmaceuticals PLC (LSE: symbol DPH) announces the conditional acquisition of the entire share capital of Putney, Inc, a leading developer of generic companion animal pharmaceuticals in the US, based in Portland, Maine.
Dechra to acquire Putney, maker of generic veterinary drugs, for $200 million  dvm360
Are RhythmOne plc, Dechra Pharmaceuticals plc and Pagegroup plc 'buys' after ...
Also reporting today was Dechra Pharmaceuticals (LSE: DPH). Its trading in the most recent full year was strong, with revenue rising by 21%.
Dechra� Pharmaceuticals PLC: Trading Update & Notice of 2016 Annual Results  PR Newswire (press release)
Should You Buy Dechra Pharmaceuticals plc, Enquest Plc & Cairn Energy PLC Today?
Pet medicines mammoth Dechra Pharmaceuticals (LSE: DPH) cheered the market with terrific half-year numbers in Monday business, propelling the stock 8% higher from the end of last week.
Checking the Numbers on Shares of Dechra Pharmaceuticals PLC (DPH.L)
Dechra Pharmaceuticals PLC (DPH.L) currently has a 50-day moving average of 1330.24, the 200-day is at 1242.26, and the 7-day is 1261.07.
Dechra Pharmaceuticals PLC: Half-Yearly Financial Report 2016
"All our business units are performing well, we are in the process of launching several new products, our international expansion plans are progressing as expected and we have made two strategic acquisitions.
Dechra Pharmaceuticals plc (LSE:DPH): Poised for Long-Term Success?
How is Dechra Pharmaceuticals going to perform in the future? Dechra Pharmaceuticals is poised for extremely high earnings growth in the future.
Dechra Pharmaceuticals (LON:DPH) Broker Updates  The De Soto Edge
Dechra Pharmaceuticals plc (DPH) Receives Add Rating from Numis Securities Ltd
Dechra Pharmaceuticals plc logo Numis Securities Ltd reaffirmed their add rating on shares of Dechra Pharmaceuticals plc (LON:DPH) in a research report released on Thursday morning. The brokerage currently has a GBX 1,520 ($18.53) target price on the ...
Dechra Pharmaceuticals plc's (DPH) Under Review Rating Reaffirmed at FinnCap
Dechra Pharmaceuticals plc logo FinnCap reiterated their under review rating on shares of Dechra Pharmaceuticals plc (LON:DPH) in a report published on Tuesday. A number of other brokerages have also commented on DPH. Panmure Gordon reissued a ...
Exercise of LTIP options  London South East (registration) (blog)
New Analyst Ratings For Dechra Pharmaceuticals (LON:DPH)  The De Soto Edge
Are GlaxoSmithKline plc, Dechra Pharmaceuticals plc & CareTech Holdings plc On ...
For example, Dechra (LSE: DPH) has been able to increase its earnings at a double-digit rate in each of the last three years, with it rising at an annualised rate of 23% during the period.